98%
921
2 minutes
20
Background & Objective: High-sensitivity cardiac troponin T (hs-cTnT) has emerged as a critical biomarker in cardiovascular diseases, particularly in congestive heart failure (CHF). This systematic review and meta-analysis aimed to assess the association between hs-cTnT levels and clinical outcomes in patients with CHF.
Methods: A comprehensive literature search was performed across multiple databases to identify studies evaluating the relationship between hs-cTnT levels and clinical outcomes in CHF. Eligible studies reported hazard ratios (HRs) or odds ratios (ORs) for all-cause mortality, cardiovascular mortality, or cardiovascular hospitalization.
Results: Elevated hs-cTnT levels were significantly associated with adverse outcomes. The pooled HR and OR for all-cause mortality were 1.70 (95% CI, 1.49-1.94) and 6.19 (95% CI, 3.88-9.86), respectively. For cardiovascular mortality, the pooled HR was 1.59 (95% CI, 1.38-1.83) and the pooled OR was 6.87 (95% CI, 3.93-12.01). For cardiovascular hospitalization, the pooled HR was 1.56 (95% CI, 1.42-1.70) and the pooled OR was 4.32 (95% CI, 2.22-8.39).
Conclusion: Elevated hs-cTnT levels are strongly associated with an increased risk of all-cause mortality, cardiovascular mortality, and cardiovascular hospitalization in patients with CHF. These findings highlight the prognostic value of hs-cTnT in the clinical management of heart failure.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308193 | PMC |
http://dx.doi.org/10.30699/ijp.2025.2057561.3440 | DOI Listing |
ACR Open Rheumatol
August 2025
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Objective: The objective of this study was to identify factors associated with detectable high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical myocardial injury associated with cardiac events in rheumatoid arthritis (RA), among patients with RA at low to intermediate atherosclerotic cardiovascular disease (ASCVD) risk.
Methods: We performed a cross-sectional cohort study among patients with RA, excluding those with pre-existing cardiovascular disease or high estimated 10-year ASCVD risk (>20%). In univariable analysis, we compared demographics, RA clinical factors, markers of inflammation, and routine lipids among patients with and without detectable hs-cTnT.
Diagnostics (Basel)
July 2025
Department of Pediatric Cardiology, Basaksehir Cam ve Sakura City Hospital, 34480 Basaksehir, Istanbul, Turkey.
: Elevated troponin levels are widely recognized as key biomarkers of myocardial injury and are frequently used in clinical decision making. However, not all instances of troponin elevation indicate true cardiac damage. In some cases, biochemical or immunological interferences may lead to false-positive results.
View Article and Find Full Text PDFDiagnostics (Basel)
July 2025
Department of Laboratory Medicine, Changi General Hospital, Singapore 529889, Singapore.
We evaluated the Sysmex Highly Integrated Single-Cartridge Luminescence Immunoassay System (HISCL) hs-cTnT assay, and compared its performance to the Roche assay, with derivation of 99th-percentile upper reference limits (99% URLs) for healthy subjects. We assessed the effect of increasing age/decreasing eGFR on the HISCL hs-cTnT. We verified assay limits of blank/detection, precision and the functional sensitivity.
View Article and Find Full Text PDFIran J Pathol
July 2025
Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Background & Objective: High-sensitivity cardiac troponin T (hs-cTnT) has emerged as a critical biomarker in cardiovascular diseases, particularly in congestive heart failure (CHF). This systematic review and meta-analysis aimed to assess the association between hs-cTnT levels and clinical outcomes in patients with CHF.
Methods: A comprehensive literature search was performed across multiple databases to identify studies evaluating the relationship between hs-cTnT levels and clinical outcomes in CHF.
Clin Biochem
July 2025
Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA. Electronic address:
Introduction: Hemolysis is a major source of interference with laboratory testing, especially for the emergency department (ED), leading to longer turnaround times for test results, repeated blood draws, delay in care delivery, and increased hospital costs. Rapid serum tubes (RST) can reduce transport-induced hemolysis, especially for samples sent via the pneumatic tube system, as compared with plasma separator tubes (PST). Previously, studies testing the efficacy of RST used larger volume 5 mL tubes to compare to 4.
View Article and Find Full Text PDF